Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; allura red ac aluminium lake; carmine - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Canada - English - Health Canada

sandoz canada incorporated - entacapone; carbidopa; levodopa - tablet - 200mg; 25mg; 100mg - entacapone 200mg; carbidopa 25mg; levodopa 100mg - catechol-o-methyltransferase (comt) inhibitors

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa, levodopa and entacapone tablets, are indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: - to substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. -  to replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. carbidopa, levodopa and entacapone tablets are contraindicated in patients: - taking nonselective monoamine oxidase (mao) inhibitors (e.g., phenelzine and tranylcypromine). these nonselective mao inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa, levodopa and entacapone tablets. -  with narrow-angle glaucoma. risk summary there are no adequate data on the developmental risk associated with the use of

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate eqv carbidopa; entacapone; levodopa - tablet, film coated - 27 mg (corresponds to 25 mg carbidopa) - carbidopa monohydrate eqv carbidopa 25 mg; entacapone 200 mg; levodopa 100 mg

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate eqv carbidopa; entacapone; levodopa - tablet, film coated - 40.5 mg (corresponds to 37.5 mg carbidopa) - carbidopa monohydrate eqv carbidopa 37.5 mg; entacapone 200 mg; levodopa 150 mg

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate eqv carbidopa; entacapone; levodopa - tablet, film coated - 13.5 mg (corresponds to 12.5 mg carbidopa) - carbidopa monohydrate eqv carbidopa 12.5 mg; entacapone 200 mg; levodopa 50 mg

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.